Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Novel Strategies for Detection, Diagnosis and Management of Non-small Cell...
jcm-logo
Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Novel Strategies for Detection, Diagnosis and Management of Non-small Cell Lung Cancer

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Respiratory Medicine".

Deadline for manuscript submissions: closed (20 July 2024) | Viewed by 5967

Special Issue Editors

Dr. Kei Suzuki

E-Mail Website
Guest Editor
1. Inova Schar Cancer Institute, 8081 Innovat Pk Dr, Fairfax, VA 22031, USA
2. Department of Surgery, Boston University School of Medicine, Boston, MA 02118, USA
Interests: surgical management of lung cancer; tumor biology of lung cancer; novel ways to screen for lung cancer
Dr. Janakiraman Subramanian

E-Mail Website
Guest Editor
Inova Schar Cancer Institute, 8081 Innovat Pk Dr, Fairfax, VA 22031, USA
Interests: surgical management of lung cancer; tumor biology of lung cancer; novel ways to screen for lung cancer

Special Issue Information

Dear Colleagues,

In this Special Issue, we aim to provide an overview of novel tools which aid in the management of non-small cell lung cancer. From a management standpoint, we hope to cover tools that could help in the detection, diagnosis and prognosis, as well as predictive markers of chemo/targeted/immune therapies. The tools encompass those developed from airway (breath print, airway epithelium), blood (liquid biopsy, cell-free DNA, molecular markers) and imaging (radiomics) data.

This Special Issue intends to bring together experts on detecting, diagnosing and managing non-small cell lung cancer, addressing all these aspects. We encourage submissions of original research or review articles that highlight the current progress, gaps in the field and future challenges, thereby promoting novel research on this topic.

Dr. Kei Suzuki
Dr. Janakiraman Subramanian
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • novel screening tool
  • liquid biopsy
  • radiomics
  • predictive marker of immunotherapy
  • non-small cell lung cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

11 pages, 1310 KiB  
Review
Novel Strategies for Lung Cancer Interventional Diagnostics
by Robert Smyth and Ehab Billatos
J. Clin. Med. 2024, 13(23), 7207; https://doi.org/10.3390/jcm13237207 - 27 Nov 2024
Cited by 2 | Viewed by 1405
Abstract
Lung cancer is a major global health issue, with 2.21 million cases and 1.80 million deaths reported in 2020. It is the leading cause of cancer death worldwide. Most lung cancers have been linked to tobacco use, with changes in cigarette composition over [...] Read more.
Lung cancer is a major global health issue, with 2.21 million cases and 1.80 million deaths reported in 2020. It is the leading cause of cancer death worldwide. Most lung cancers have been linked to tobacco use, with changes in cigarette composition over the years contributing to shifts in cancer types and tumor locations within the lungs. Additionally, there is a growing incidence of lung cancer among never-smokers, particularly in East Asia, which is expected to increase the global burden of the disease. The classification of non-small cell lung cancer (NSCLC) into distinct subtypes is crucial for treatment efficacy and patient safety, especially as different subtypes respond differently to chemotherapy. For instance, certain chemotherapeutic agents are more effective for adenocarcinoma than for squamous carcinoma, which has led to the exclusion of squamous carcinoma from treatments like Bevacizumab due to safety concerns. This necessitates accurate histological diagnosis, which requires sufficient tissue samples from biopsies. However, acquiring adequate tissue is challenging due to the complex nature of lung tumors, patient comorbidities, and potential complications from biopsy procedures, such as bleeding, pneumothorax, and the purported risk of local recurrence. The need for improved diagnostic techniques has led to the development of advanced technologies like electromagnetic navigation bronchoscopy (ENB), radial endobronchial ultrasound (rEBUS), and robotic bronchoscopy. ENB and rEBUS have enhanced the accuracy and safety of lung biopsies, particularly for peripheral lesions, but both have limitations, such as the dependency on the presence of a bronchus sign. Robotic bronchoscopy, which builds on ENB, offers greater maneuverability and stability, improving diagnostic yields. Additionally, new imaging adjuncts, such as Cone Beam Computed Tomography (CBCT) and augmented fluoroscopy, further enhance the precision of these procedures by providing real-time, high-resolution imaging. These advancements are crucial as lung cancer is increasingly being detected at earlier stages due to screening programs, which require minimally invasive, accurate diagnostic methods to improve patient outcomes. This review aims to provide a comprehensive overview of the current challenges in lung cancer diagnostics and the innovative technological advancements in this rapidly evolving field, which represents an increasingly exciting career path for aspiring pulmonologists. Full article
(This article belongs to the Special Issue Novel Strategies for Detection, Diagnosis and Management of Non-small Cell Lung Cancer)
►▼ Show Figures

Figure 1

13 pages, 282 KiB  
Review
Innovations in Early Lung Cancer Detection: Tracing the Evolution and Advancements in Screening
by Lindsey B. Cotton, Peter B. Bach, Chris Cisar, Caitlin A. Schonewolf, Demetria Tennefoss, Anil Vachani, Lisa Carter-Bawa and Ali H. Zaidi
J. Clin. Med. 2024, 13(16), 4911; https://doi.org/10.3390/jcm13164911 - 20 Aug 2024
Cited by 2 | Viewed by 4126
Abstract
Lung cancer mortality rates, particularly non-small cell lung cancer (NSCLC), continue to present a significant global health challenge, and the adoption of lung cancer screening remains limited, often influenced by inequities in access to healthcare. Despite clinical evidence demonstrating the efficacy of annual [...] Read more.
Lung cancer mortality rates, particularly non-small cell lung cancer (NSCLC), continue to present a significant global health challenge, and the adoption of lung cancer screening remains limited, often influenced by inequities in access to healthcare. Despite clinical evidence demonstrating the efficacy of annual screening with low-dose computed tomography (LDCT) and recommendations from medical organizations including the U.S. Preventive Services Task Force (USPSTF), the national lung cancer screening uptake remains around 5% among eligible individuals. Advancements in the clinical management of NSCLC have recently become more personalized with the implementation of blood-based biomarker testing. Extensive research into tumor-derived cell-free DNA (cfDNA) through fragmentation offers a novel method for improving early lung cancer detection. This review assesses the screening landscape, explores obstacles to lung cancer screening, and discusses how a plasma whole genome fragmentome test (pWGFrag-Lung) can improve lung cancer screening participation and adherence. Full article
(This article belongs to the Special Issue Novel Strategies for Detection, Diagnosis and Management of Non-small Cell Lung Cancer)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop